GeneCentric is a pioneering brand dedicated to the development and commercialization of biomarkers and companion diagnostics that shape the future of cancer treatment. With a mission to define cancer drug responders and enhance patient outcomes, GeneCentric applies its innovative rT(I)ME Explorer Platform to identify RNA-based gene signatures. These gene signatures, in the form of molecular subtypes and drug response predictors, enable the development of precision cancer drugs.

GeneCentric's approach involves the creation of high-resolution gene signatures that are either prognostic or predictive and are applicable to immune-based, targeted, and other cancer therapeutics. By collaborating with strategic partners in the diagnostics, pharmaceutical, and biotechnology industries, GeneCentric continues to expand its pipeline of gene signatures and related diagnostics. Led by a team of experienced scientists and executives, GeneCentric is committed to driving the future of personalized cancer treatment through cutting-edge technology and strategic collaborations